- US12612382utility2026Process for Preparing 6-substituted-1-(2h)-isoquinolinones and Intermediate Compound0 cites
- US12595449utility2026Integrated System for 3D Tissue Culture0 cites
- US12590078utility2026Inhibiting USP190 cites
- US12590087utility2026Inhibiting USP360 cites
- US12479807utility2025Methods Using HDAC11 Inhibitors0 cites
- US12304904utility2025Bicyclic [4,6,0] Hydroxamic Acids as HDAC Inhibitors0 cites
- US12264137utility20253-aryl-4-amido-bicyclic [4,5,0] Hydroxamic Acids as HDAC Inhibitors0 cites
- US12252490utility2025Inhibiting Deubiquitinase USP25 and USP280 cites
- US12213969utility20252-spiro-5- and 6-hydroxamic Acid Indanes as HDAC Inhibitors0 cites
- US12162888utility2024Carboxamides as Ubiquitin-specific Protease Inhibitors0 cites
- US12116362utility2024Monocyclic Compounds Useful as GPR120 Modulators0 cites
- US12018030utility2024Pyrrolo and Pyrazolopyrimidines as Ubiquitin-specific Protease 7 Inhibitors0 cites
- US11919839utility2024Alpha-cinnamide Compounds and Compositions as HDAC8 Inhibitors0 cites
- US11919891utility2024Bicyclic Compounds Useful as GPR120 Modulators0 cites
- US11891365utility20243-alkyl-4-amido-bicyclic [4,5,0] Hydroxamic Acids as HDAC Inhibitors0 cites
- US11795171utility2023Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-specific Protease 7 Inhibitors0 cites
- US11739071utility2023Quinazolinones and Azaquinazolinones as Ubiquitin-specific Protease 7 Inhibitors0 cites
- US11730721utility20232-spiro-5- and 6-hydroxamic Acid Indanes as HDAC Inhibitors0 cites
- US11702412utility2023Bicyclic [4,6,0] Hydroxamic Acids as HDAC Inhibitors0 cites
- US11548886utility2023Monocyclic Compounds Useful as GPR120 Modulators0 cites